Three antibiotics, three different AMR battles: why Innoviva’s Prix Galien triple could matter beyond the awards
Innoviva’s XACDURO, ZEVTERA and NUZOLVENCE reach the 2026 Prix Galien finals, spotlighting a growing anti-infective portfolio.
Pharma & Biotech